Generalized Safety and Efficacy of Simplified Intravenous Thrombolysis Treatment (SMART) Criteria in Acute Ischemic Stroke: The MULTI SMART Study

Journal of Stroke and Cerebrovascular Diseases

Volumn 25, Issue 5, 2016, Pages 1110-1118

  Sørensen, Sigrid B ^a,b   Barazangi, Nobl ^a,c   Chen, Charlene ^a,c   Wong, Christine ^a,c   Grosvenor, David ^a,d   Rose, Jack ^a,c   Bedenk, Ann ^a,c   Morrow, Megan ^a,c   McDermott, Dan ^a   Hove, Jens D ^b,e   Tong, David C ^a,c  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c CPMC Department of Neurosciences   (United States)

^d PALO ALTO MEDICAL FOUNDATION   (United States)

^e HVIDOVRE HOSPITAL   (Denmark)

Author keywords

Ischemic stroke; stroke management; telemedicine; thrombolysis

Indexed keywords

ALTEPLASE; TENECTEPLASE; FIBRINOLYTIC AGENT; RECOMBINANT PROTEIN; TISSUE PLASMINOGEN ACTIVATOR;

AGED; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLASSIFICATION; DRUG CONTRAINDICATION; FEMALE; FIBRINOLYTIC THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; PATIENT SAFETY; PRIORITY JOURNAL; RANKIN SCALE; RETROSPECTIVE STUDY; SELF EXPANDING STENT; SIMPLIFIED INTRAVENOUS THROMBOLYSIS TREATMENT CRITERIA; STENT RETRIEVER; TREATMENT OUTCOME; ADVERSE EFFECTS; CALIFORNIA; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; DECISION SUPPORT SYSTEM; DISABILITY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; RISK FACTOR; STATISTICAL MODEL; STROKE; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CALIFORNIA; CHI-SQUARE DISTRIBUTION; DECISION SUPPORT TECHNIQUES; DISABILITY EVALUATION; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; INFUSIONS, INTRAVENOUS; INTRACRANIAL HEMORRHAGES; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84958206217     PISSN: 10523057     EISSN: 15328511     Source Type: Journal    
DOI: 10.1016/j.jstrokecerebrovasdis.2016.01.016     Document Type: Article

References (33)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group Tissue plasminogen activator for acute ischemic stroke N Engl J Med 333 1995 1581 1587
2. N. Wahlgren, N. Ahmed, A. Davalos, and et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study Lancet 369 2007 275 282
3. W. Hacke, M. Kaste, C. Fieschi, and et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators Lancet 352 1998 1245 1251
4. O. Adeoye, R. Hornung, P. Khatri, and et al. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years Stroke 42 2011 1952 1955
5. Tong D., M.J. Reeves, A.F. Hernandez, and et al. Times from symptom onset to hospital arrival in the Get with the Guidelines - Stroke Program 2002 to 2009: temporal trends and implications Stroke 43 2012 1912 1917
6. W. Hacke, M. Kaste, E. Bluhmki, and et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke N Engl J Med 359 2008 1317 1329
7. Tong D. Are all IV thrombolysis exclusion criteria necessary? Being SMART about evidence-based medicine Neurology 76 2011 1780 1781
8. B.M. Demaerschalk Challenging the validity of imposing contraindications to thrombolysis for acute ischemic stroke Neurology 77 2011 1862 1863
9. IST-3 Collaborative Group The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial Lancet 379 2012 2352 2363
10. N.K. Mishra, N. Ahmed, G. Andersen, and et al. Thrombolysis in very elderly people: controlled comparison of SITS International Stroke Thrombolysis Registry and Virtual International Stroke Trials Archive BMJ 341 2010 c6046
11. J. De Keyser, Z. Gdovinova, M. Uyttenboogaart, and et al. Intravenous alteplase for stroke: beyond the guidelines and in particular clinical situations Stroke 38 2007 2612 2618
12. E. Bluhmki, A. Chamorro, A. Davalos, and et al. Stroke treatment with alteplase given 3.0-4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial Lancet Neurol 8 2009 1095 1102
13. Helsinki Stroke Thrombolysis Registry Group Intravenous thrombolysis for acute ischemic stroke patients presenting with mild symptoms Int J Stroke 8 2013 293 299
14. D. Manawadu, S. Bodla, J. Keep, and et al. An observational study of thrombolysis outcomes in wake-up ischemic stroke patients Stroke 44 2013 427 431
15. Tong D., N. Barazangi, J. Rose, and et al. Increasing IV rt-PA use using modern eligibility criteria. The Simplified Management of Acute stroke using Revised Treatment (SMART) criteria study: feasibility, safety and efficacy American Academy of Neurology Annual Conference, Toronto CN 2010
16. Tong D., J. Rose, J. Barakos, and et al. Increasing thrombolytic treatment rates: results utilizing revised treatment criteria and a multidisciplinary stroke education program International Stroke Conference, New Orleans, LA 2008
17. H.P. Adams Jr, B.H. Bendixen, L.J. Kappelle, and et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment Stroke 24 1993 35 41
18. H.P. Adams Jr, G. del Zoppo, M.J. Alberts, and et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists Stroke 38 2007 1655 1711
19. G.J. Del Zoppo, J.L. Saver, E.C. Jauch, and et al. Expansion of the time window for treatment of acute ischemic stroke with intravenous tissue plasminogen activator: a science advisory from the American Heart Association/American Stroke Association Stroke 40 2009 2945 2948
20. Practice advisory: thrombolytic therapy for acute ischemic stroke - summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 47 1996 835 839
21. European Agency for Evaluation of Medicinal products Actilyse, 2013 Available at http://www.medicines.org.uk/emc/medicine/308/SPC/Actilyse/ Accessed April 26, 2015
22. Genentech Activase (Alteplase), 2015 Available at http://www.gene.com/download/pdf/activase-prescribing.pdf Accessed April 26, 2015
23. S.E. Kasner, J.A. Chalela, J.M. Luciano, and et al. Reliability and validity of estimating the NIH stroke scale score from medical records Stroke 30 1999 1534 1537
24. J.M. Wardlaw, V. Murray, E. Berge, and et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis Lancet 379 2012 2364 2372
25. M. Guillan, A. Alonso-Canovas, J. Garcia-Caldentey, and et al. Off-label intravenous thrombolysis in acute stroke Eur J Neurol 19 2012 390 394
26. A. Meretoja, J. Putaala, T. Tatlisumak, and et al. Off-label thrombolysis is not associated with poor outcome in patients with stroke Stroke 41 2010 1450 1458
27. M. Rubiera, M. Ribo, E. Santamarina, and et al. Is it time to reassess the SITS-MOST criteria for thrombolysis?: a comparison of patients with and without SITS-MOST exclusion criteria Stroke 40 2009 2568 2571
28. C.E. Kvistad, N. Logallo, L. Thomassen, and et al. Safety of off-label stroke treatment with tissue plasminogen activator Acta Neurol Scand 128 2013 48 53
29. E.E. Smith, A.R. Abdullah, I. Petkovska, and et al. Poor outcomes in patients who do not receive intravenous tissue plasminogen activator because of mild or improving ischemic stroke Stroke 36 2005 2497 2499
30. E.E. Smith, G.C. Fonarow, M.J. Reeves, and et al. Outcomes in mild or rapidly improving stroke not treated with intravenous recombinant tissue-type plasminogen activator: findings from get with the guidelines-stroke Stroke 42 2011 3110 3115
31. National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience Ann Emerg Med 46 2005 243 252
32. S. Mustanoja, A. Meretoja, J. Putaala, and et al. Outcome by stroke etiology in patients receiving thrombolytic treatment: descriptive subtype analysis Stroke 42 2011 102 106
33. S. Prabhakaran, K. O'Neill, L. Stein-Spencer, and et al. Prehospital triage to primary stroke centers and rate of stroke thrombolysis JAMA Neurol 70 2013 1126 1132